Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study
PurposeThis study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.Material and methodsIn this study, data of patients with unr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1143578/full |
| _version_ | 1827823188439990272 |
|---|---|
| author | Kunpeng Wu Kunpeng Wu Kunpeng Wu Yahua Li Yahua Li Yahua Li Zongming Li Zongming Li Zongming Li Zihe Zhou Zihe Zhou Zihe Zhou Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yifan Li Yifan Li Yifan Li Xinwei Han Xinwei Han Xinwei Han Peng Chen Kewei Ren Kewei Ren Kewei Ren |
| author_facet | Kunpeng Wu Kunpeng Wu Kunpeng Wu Yahua Li Yahua Li Yahua Li Zongming Li Zongming Li Zongming Li Zihe Zhou Zihe Zhou Zihe Zhou Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yifan Li Yifan Li Yifan Li Xinwei Han Xinwei Han Xinwei Han Peng Chen Kewei Ren Kewei Ren Kewei Ren |
| author_sort | Kunpeng Wu |
| collection | DOAJ |
| description | PurposeThis study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.Material and methodsIn this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).ResultsA total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment.ConclusionTACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable. |
| first_indexed | 2024-03-12T02:08:36Z |
| format | Article |
| id | doaj.art-d5509919a0854540b25e0677afbd0dc5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T02:08:36Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d5509919a0854540b25e0677afbd0dc52023-09-06T21:01:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.11435781143578Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective studyKunpeng Wu0Kunpeng Wu1Kunpeng Wu2Yahua Li3Yahua Li4Yahua Li5Zongming Li6Zongming Li7Zongming Li8Zihe Zhou9Zihe Zhou10Zihe Zhou11Xiaoyong Ge12Xiaoyong Ge13Xiaoyong Ge14Yifan Li15Yifan Li16Yifan Li17Xinwei Han18Xinwei Han19Xinwei Han20Peng Chen21Kewei Ren22Kewei Ren23Kewei Ren24Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Institute of Zhengzhou University, Zhengzhou, Henan, ChinaInterventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, ChinaPurposeThis study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.Material and methodsIn this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).ResultsA total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment.ConclusionTACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable.https://www.frontiersin.org/articles/10.3389/fonc.2023.1143578/fullTACEtargeted therapyimmunotherapygastric or gastroesophageal junction cancercomprehensive therapy |
| spellingShingle | Kunpeng Wu Kunpeng Wu Kunpeng Wu Yahua Li Yahua Li Yahua Li Zongming Li Zongming Li Zongming Li Zihe Zhou Zihe Zhou Zihe Zhou Xiaoyong Ge Xiaoyong Ge Xiaoyong Ge Yifan Li Yifan Li Yifan Li Xinwei Han Xinwei Han Xinwei Han Peng Chen Kewei Ren Kewei Ren Kewei Ren Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study Frontiers in Oncology TACE targeted therapy immunotherapy gastric or gastroesophageal junction cancer comprehensive therapy |
| title | Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study |
| title_full | Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study |
| title_fullStr | Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study |
| title_full_unstemmed | Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study |
| title_short | Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study |
| title_sort | transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer a single arm single center retrospective study |
| topic | TACE targeted therapy immunotherapy gastric or gastroesophageal junction cancer comprehensive therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1143578/full |
| work_keys_str_mv | AT kunpengwu transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT kunpengwu transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT kunpengwu transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yahuali transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yahuali transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yahuali transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zongmingli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zongmingli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zongmingli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zihezhou transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zihezhou transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT zihezhou transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xiaoyongge transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xiaoyongge transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xiaoyongge transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yifanli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yifanli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT yifanli transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xinweihan transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xinweihan transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT xinweihan transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT pengchen transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT keweiren transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT keweiren transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy AT keweiren transcatheterarterialchemoembolizationcombinedwithapatinibandcamrelizumabforunresectableadvancedgastricorgastroesophagealjunctioncancerasinglearmsinglecenterretrospectivestudy |